Incyte beefs up portfolio with FDA nod for rare bile duct cancer therapy Pemazyre

20th April 2020 Uncategorised 0

As a partner with Novartis on JAK inhibitor Jakafi, Incyte has pinned its future fortunes on the success of the blockbuster med, particularly with COVID-19 trials ongoing. But Incyte has been looking forward to a trio of late-stage candidates coming through, and now the first of those has scored an FDA nod.

More: Incyte beefs up portfolio with FDA nod for rare bile duct cancer therapy Pemazyre
Source: fierce